Interview with Chen Chun Lin, Co-Chairman, Medicilon/MPI Preclinical Research…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Address: 585 Chuanda Road, Pudong New AreaShanghai, 201200,China
Tel: +86 21 31268381
Web: http://www.medicilon-mpi.com/
As a newly formed joint venture located in China, Medicilon/MPI Preclinical Research Shanghai provides a portfolio of preclinical discovery and development services to pharmaceutical and biotechnology companies.
Medicilon/MPI Preclinical Research Shanghai has brought together the best of its parent companies, Shanghai Medicilon and MPI Research, to assure top quality, on-time GLP and non-GLP studies.
toxicology services
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the…
Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either…
The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention…
See our Cookie Privacy Policy Here
